Market Research Industry Reports

ARMO Biosciences Inc (ARMO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Summary

ARMO Biosciences Inc (ARMO Biosciences) is an immuno-oncology company that develops tumors treatment drugs. The company develops anti-programmed cell death protein 1 checkpoint inhibitors and other therapeutic cytokines. Its portfolio of pipeline drug candidates includes AM0010, AM0015, AM0012 and AM0001. ARMO Biosciencess lead immunotherapy AM0010, is a PEGylated form of recombinant human IL-10. Its pipeline comprises various validated product candidates aimed at treating a variety of cancers in combination with standard of care and emerging immunotherapies. ARMO Biosciences is headquartered in Redwood City, California, the US.

ARMO Biosciences Inc (ARMO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.




ARMO Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ARMO Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ARMO Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ARMO Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
ARMO Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
ARMO Biosciences Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Armo Biosciences Completes Acquisition Of Prevascar Assets Of Renovo For US$0.7 Million 12
Venture Financing 13
ARMO Biosciences Raises USD67 Million in Series C-1 Financing 13
Armo Biosciences Raises USD50 Million in Series C Financing 15
Armo Biosciences Raises USD30 Million in Series B Financing 17
ARMO Biosciences Raises US$20 Million In Series A Financing 18
Licensing Agreements 20
ARMO BioSciences Enters into Licensing Agreement with Open Monoclonal 20
ARMO Biosciences Enters into Licensing Agreement with Merck 21
Equity Offering 22
ARMO BioSciences Raises USD128 Million in IPO 22
ARMO Biosciences Inc - Key Competitors 23
ARMO Biosciences Inc - Key Employees 24
ARMO Biosciences Inc - Locations And Subsidiaries 25
Head Office 25
Recent Developments 26
Corporate Communications 26
Nov 28, 2017: ARMO BioSciences Appoints Herb Cross as Chief Financial Officer 26
Jun 28, 2017: ARMO BioSciences Appoints Naiyer A. Rizvi, M.D. to Board of Directors 27
Apr 26, 2017: ARMO BioSciences Appoints Pierre Legault to Board of Directors 28
Product News 29
04/21/2017: ARMO BioSciences Announces Clinical Data Presentation for Immunotherapy AM0010 at the 12th European International Kidney Cancer Symposium 29
04/20/2017: ARMO BioSciences Announces Clinical Data Presentations for Immunotherapy AM0010 at ASCO 2017 Annual Meeting 30
Clinical Trials 32
Dec 09, 2017: ARMO BioSciences Presents Data from its Phase 1b Trial in Non-Small Cell Lung Cancer at ESMO Immuno Oncology Congress 2017 32
Dec 08, 2017: ARMO BioSciences Presents Efficacy Data from its Phase 1b Trial in Patients with Metastatic Renal Cell Carcinoma at ESMO Immuno-Oncology Congress 2017 33
Sep 09, 2017: ARMO BioSciencess Phase 1b Trials Demonstrate Continued Promising Response Rates and Survival in Patients with Advanced Pancreatic Cancer, NSCLC, and RCC 34
Jun 29, 2017: ARMO BioSciences Presents Clinical Data on Immunotherapy AM0010 in Advanced Pancreatic Cancer at ESMO World Congress on Gastrointestinal Cancer 2017 36
Jun 03, 2017: ARMO BioSciences Announces Encouraging Survival Data Observed in Patients with Advanced Pancreatic Cancer in Phase 1/1b Trial of Immunotherapy AM0010 37
May 30, 2017: ARMO BioSciences Announces Promising Response Rates and Survival Data in Patients with Advanced NSCLC and RCC from Phase 1/1b Trial for Immunotherapy AM0010 with Checkpoint Inhibitors 39
Mar 29, 2017: ARMO BioSciences Announces First Patient Dosed in Pivotal Phase 3 Trial of Immunotherapy AM0010 for Advanced Pancreatic Cancer 41
Jan 20, 2017: ARMO BioSciences Presents New Phase 1b Clinical Data for AM0010 in Advanced Pancreatic Cancer Patients at 2017 Gastrointestinal Cancers Symposium 42
Appendix 43
Methodology 43
About GlobalData 43
Contact Us 43
Disclaimer 43

List Of Tables

List of Tables
ARMO Biosciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
ARMO Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ARMO Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ARMO Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ARMO Biosciences Inc, Deals By Therapy Area, 2012 to YTD 2018 9
ARMO Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Armo Biosciences Completes Acquisition Of Prevascar Assets Of Renovo For US$0.7 Million 12
ARMO Biosciences Raises USD67 Million in Series C-1 Financing 13
Armo Biosciences Raises USD50 Million in Series C Financing 15
Armo Biosciences Raises USD30 Million in Series B Financing 17
ARMO Biosciences Raises US$20 Million In Series A Financing 18
ARMO BioSciences Enters into Licensing Agreement with Open Monoclonal 20
ARMO Biosciences Enters into Licensing Agreement with Merck 21
ARMO BioSciences Raises USD128 Million in IPO 22
ARMO Biosciences Inc, Key Competitors 23
ARMO Biosciences Inc, Key Employees 24

List Of Figures

List of Figures
Genesis Energy LP, Performance Chart (2013 - 2017) 28
Genesis Energy LP, Ratio Charts 30
Genesis Energy LP, Oil & Gas, Deals By Year, 2012 to YTD 2018 31
Genesis Energy LP, Oil & Gas, Deals by Type, 2012 to YTD 2018 36

The Global Military Vehicular Armor Market Survey Outlook 2018-2028

The Global Military Vehicular Armor Market Survey Outlook 2018-2028The Global Military Vehicular Armor Market Survey Outlook 2018-2028, examines executives opinion on emerging trend in the vehicular armor market and the

USD 1950View Report

Global Defense Armored Vehicle MRO Market Research Report 2018

Defense Armored Vehicle MRO Report by Material, Application, and Geography Global Forecast to 2022 is a professional and in-depth research report on the worlds major regional market conditions, focusing

USD 2850View Report

Catalyst Biosciences Inc (CBIO) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Catalyst Biosciences Inc (Catalyst), formerly Targacept Inc is a clinical-stage biopharmaceutical company that develops novel medicines to treat hematology indications. The company discovers and develops next generation biopharmaceuticals based on

USD 250View Report

Precision Biosciences Inc - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Precision Biosciences Inc (Precision BioSciences) is a provider of site-specific genome modification services. The company develops technology based on the production of custom-made DNA-cutting enzymes. It offers various solutions in

USD 250View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 250
  • Site Licence    USD 500
  • Enterprise Wide Licence    USD 750
$ 250

Reports Details

Published Date : Apr 2018
No. of Pages :43
Country :United States of America
Category :Pharmaceuticals and Healthcare
Publisher :GlobalData
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube